An early trial of botensilimab plus balstilimab showed an estimated 48% three-year survival rate in recurrent ovarian cancer. Here is what the data mean.
Estimated 48% of Women with Heavily Treated Ovarian Cancer Were Alive at Three Years in Small Immunotherapy Trial
by | Oct 7, 2026 | Uncategorized | 0 comments
Recent Comments